MSD Launches Winrevair (Sotatercept) in China – First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension
Merck & Co., Inc. (MSD; NYSE: MRK) announced the official commercial launch of Winrevair (sotatercept)...
Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced a strategic joint venture agreement...
Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism
Everest Medicines (HKG: 1952) announced a strategic licensing agreement with domestic peer Corxel Pharmaceuticals Limited...
Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate
Guangzhou Lupeng Pharmaceutical Co., Ltd. announced it has received marketing approval via priority review pathway...
China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development
China’s National Healthcare Commission (NHC) announced the release of its sixth batch of pediatric drugs...
Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced it has received regulatory approval from China’s...
Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced it has received clinical trial approval from...
Shanghai Bao Pharmaceuticals’ KJ103 NDA Accepted by NMPA – First-in-Class IgG Degrading Enzyme for Highly Sensitized Kidney Transplant Patients
Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) announced that the National Medical Products Administration (NMPA)...
Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in...
Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies
Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple...
Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases
Gilead Sciences (NASDAQ: GILD) and Lakefront Biotherapeutics NV (NASDAQ: LKFT) announced the successful completion of...
Teva Launches Ahzantive Biosimilar to Bayer’s Eylea Across Europe – Expanding Access to Retinal Disease Treatments
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version...
Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design
Pfizer (NYSE: PFE) announced a strategic license agreement with Chai Discovery, an artificial intelligence company...
Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy – Once-Yearly ASO with Novel Chemical Structure
Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food...
Innovent Biologics Reports Positive Phase III Results for IBI343 in Advanced Gastric Cancer – CLDN18.2-Targeting ADC Files NDA with NMPA
Innovent Biologics (HKG: 1801) announced that the pre-specified first interim analysis from the global Phase...
Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD
Everest Medicines (HKG: 1952) announced a licensing agreement with fellow Chinese biopharmaceutical company Beijing Mabworks...
Jiangsu Vcare PharmaTech Secures NMPA Approval for Eratrectinib – Next-Generation TRK Inhibitor with Enhanced Brain Penetration and Circular Molecular Structure
Jiangsu Vcare PharmaTech Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...
GE HealthCare Secures FDA 510(k) Clearance for MIM Contour ProtégéAI+ 2.0 – AI Auto-Contouring Platform with Predetermined Change Control Plan
GE HealthCare (NASDAQ: GEHC) announced it has received 510(k) clearance from the United States Food...
Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA)...